{"clinical_study": {"@rank": "56", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04315896"}, "id_info": {"org_study_id": "HidroxycloroquinaCOVID19", "nct_id": "NCT04315896"}, "brief_title": "Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)", "acronym": "HYDRA", "official_title": "Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)", "sponsors": {"lead_sponsor": {"agency": "National Institute of Respiratory Diseases, Mexico", "agency_class": "Other"}, "collaborator": {"agency": "Sanofi", "agency_class": "Industry"}}, "source": "National Institute of Respiratory Diseases, Mexico", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No", "is_us_export": "No"}, "brief_summary": {"textblock": "Double blinded randomized clinical trial designed to evaluate the security and efficacy of\n      hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators\n      hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause\n      hospital mortality in patients with severe respiratory COVID-19 disease."}, "detailed_description": {"textblock": "Since hydroxychloroquine is a low cost and safe anti-malaria drug that has proven effects\n      against COVID-19 in vitro. The investigators aim to study the security and efficacy of this\n      drug in trough a double blinded randomized clinical trial. Recruited patients with severe\n      respiratory disease from COVID-19 will be randomized to an intervention group (400mg per day\n      dose of hydroxychloroquine) and placebo. The investigators' main outcome will be all cause\n      hospital mortality. The investigators hypothesize that a 400mg per day dose of\n      hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with\n      severe respiratory COVID-19 disease. Results will be compared in an intention to treat\n      analysis. All clinical, analysis and data team members will be blinded to treatment\n      assignment."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "March 23, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "March 22, 2021"}, "primary_completion_date": {"@type": "Anticipated", "#text": "October 31, 2020"}, "phase": "Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "intervention_model_description": "Double blinded, randomized controlled trial", "primary_purpose": "Treatment", "masking": "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)", "masking_description": "Clinical practitioners and data analysts will remain blinded all through the study. Blinding will end in case the attending physician considers the patient should abandon the study or some of the exclusion/elimination criteria apply."}, "primary_outcome": {"measure": "All-cause hospital mortality", "time_frame": "From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days", "description": "incidence of all-cause mortality"}, "secondary_outcome": [{"measure": "Length of hospital stay", "time_frame": "From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days", "description": "Days from ER admission to hospital discharge"}, {"measure": "Need of mechanical ventilation", "time_frame": "From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days", "description": "need of invasive or non invasive mechanical ventilation"}, {"measure": "Ventilator free days", "time_frame": "From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days", "description": "28 minus days without invasive ventilation support in patients with invasive mechanical ventilation at randomization"}, {"measure": "Grade 3-4 adverse reaction", "time_frame": "From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days", "description": "Adverse Reactions"}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "500"}, "condition": ["COVID-19", "Severe Acute Respiratory Syndrome"], "arm_group": [{"arm_group_label": "treatment", "arm_group_type": "Active Comparator", "description": "Hydroxychloroquine tablet 200mg every 12 hours for 10 days."}, {"arm_group_label": "placebo", "arm_group_type": "Placebo Comparator", "description": "identical placebo, one tablet every 12 hours for 10 days"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Hydroxychloroquine", "description": "hydroxychloroquine 400mg day for 10 days", "arm_group_label": "treatment"}, {"intervention_type": "Drug", "intervention_name": "Placebo oral tablet", "description": "Placebo oral tablet", "arm_group_label": "placebo"}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          1. Signed informed consent\n\n          2. negative pregnancy test in women\n\n          3. COVID-19 confirmed by rtPCR in any respiratory sample.\n\n          4. Severe COVID-19 disease defined as any from the following:\n\n               1. Pulse oximetry less than 91% or a 3% drop from base pulse oximetry or need to\n                  increase supplementary oxygen in chronic hypoxia\n\n               2. Need for mechanical ventilation (invasive or non invasive )\n\n               3. Sepsis/septic shock.\n\n        Exclusion Criteria:\n\n          1. history of anaphylactic shock to hydroxychloroquine.\n\n          2. History of previous administration of chloroquine or hydroxychloroquine (within 1\n             month)\n\n          3. decision of attending physician by any reason.\n\n          4. History of chronic hepatic disease (Child-Pugh B or C)\n\n          5. History of Chronic renal disease (GFR less than 30)"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No"}, "overall_official": [{"last_name": "Carmen Hernandez-C\u00e1rdenas, MD. MSc.", "role": "Principal Investigator", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Luis-Felipe Jurado-Camacho, MD", "role": "Study Director", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Ireri Thirion-Romero, MD. MSc", "role": "Study Chair", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Sebastian Rodriguez-Llamazares, MD.MPH", "role": "Study Chair", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Rogelio Perez-Padilla, MD. PhD", "role": "Study Director", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Cristobal Guadarrama, MD MSc", "role": "Study Chair", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}, {"last_name": "Joel Vasquez-P\u00e9rez, MD", "role": "Study Chair", "affiliation": "National Institute of Respiratory Diseases - M\u00e9xico"}], "overall_contact": {"last_name": "Carmen Hernandez-C\u00e1rdenas, MD. MSc", "phone": "54871700", "phone_ext": "5213", "email": "cmhcar@hotmail.com"}, "overall_contact_backup": {"last_name": "Rogelio Perez-Padilla, MD. PhD.", "phone": "54871700", "email": "perezpad@gmail.com"}, "verification_date": "March 2020", "study_first_submitted": "March 18, 2020", "study_first_submitted_qc": "March 18, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 20, 2020"}, "last_update_submitted": "March 18, 2020", "last_update_submitted_qc": "March 18, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 20, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": ["COVID-19", "Severe acute respiratory syndrome"], "condition_browse": {"mesh_term": ["Severe Acute Respiratory Syndrome", "Coronavirus Infections"]}, "intervention_browse": {"mesh_term": "Hydroxychloroquine"}, "patient_data": {"sharing_ipd": "Undecided", "ipd_description": "As requested by other investigators."}}}